Cardiac surgery in three patients infected with the human immunodeficiency virus.
Human immunodeficiency virus infection (HIV) is the fourth leading cause of death worldwide.1 Recently, the introduction of highly active antiretroviral therapy (HAART) improved the survival rate of HIV-infected patients. However, the number of HIV-infected patients to be referred for cardiac surgery will increase because cardiovascular risk is increased with the use of HAART. Herein, we report three HIV-infected patients who underwent open heart surgery with cardiopulmonary bypass; we followed their progress by monitoring their CD4+ T-lymphocyte counts. Based on our experience, it seems that cardiopulmonary bypass does not accelerate progression of HIV disease.
Namai
Asako
A
Department of Cardiovascular Surgery, National Hospital Organization Sendai Medical Center, 2-8-8 Miyagino, Miyaginoku, Sendai, 983-8520, Japan.
Sakurai
Masahiro
M
Akiyama
Masatoshi
M
D018791:CD4 Lymphocyte Count; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000601:surgery; D006349:Heart Valve Diseases / Q000150:complications / Q000276:immunology / Q000601:surgery*; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
Am Heart J. 2006 Jun;151(6):1147-55
16781213
J Clin Lab Immunol. 1987 Jan;22(1):1-5
2882027
J Hepatobiliary Pancreat Surg. 2004;11(3):207-10
15235896
Ann Thorac Surg. 2000 Nov;70(5):1698-9
11093516
Ann Thorac Surg. 1993 May;55(5):1104-7; discussion 1107-8
8494417
Arch Intern Med. 2005 Feb 28;165(4):416-23
15738371
J Card Surg. 1997 Mar-Apr;12(2):98-101
9271729
J Card Surg. 1992 Sep;7(3):240-4
1392232